Abstract from the SUS Study to be presented during the ESSFN Congress in Stockholm in September
For the first time results from the CLS-sponsored study at Skåne University Hospital (SUS) will be presented and discussed during an international scientific congress. We are happy to share that the abstract OP033 “Laser interstitial thermal therapy using an uncooled laser catheter in a diagnostic MR suite” by Dr Hjalmar Bjartmarz et al, has been accepted for oral presentation at the ESSFN (European Society of Stereotactic and Functional Neurosurgery) congress in Stockholm, September 28.
The authors write that “Laser interstitial thermal therapy (LITT) has emerged as an alternative to open surgery for both primary and secondary brain tumors. Additionally, thermal ablation by laser can be Laser interstitial thermal therapy (LITT) has emerged as an alternative to open surgery for both primary and secondary brain tumors”. In the study conducted by the team at SUS, five patients with recurrent glioblastoma were included and single or multiple ablations performed.
In the abstract the authors discuss the advantages of using a non-cooled laser catheter system with thermometry (TRANBERG® Laser Applicator and Thermoguide Workstation by CLS), together with a MRI compatible navigation system (ClearPoint® Neuro Navigation System), and how patient risks are minimized using a workflow where both catheter placement and ablation are performed inside a diagnostic MR suite.
Their conclusion is that “LITT using a non-cooled laser catheter inside an outpatient MRI suite was feasible and reproducible. The procedure may reduce risks associated with LITT procedures.”
The full abstract is published on the ESSFN website (search speaker: Bjartmarz):
Further recommended reading
Both Skåne University Hospital, and Swedish TV news (SVT Nyheter Skåne), have previously reported from the study:
- Press-release-from-skane-university-hospital-on-the-ongoing-study-using-cls-products-for-neurosurgery-inside-the-mri-camera
- Listen-to-a-patient-story
For more information, please contact:
Liselotte Nilsson, VP Marketing, Clinical Laserthermia Systems AB
email: lotta.nilsson@clinicallaser.com
phone: +46 (0)703 736443
About CLS and TRANBERG
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. All components of the TRANBERG®|Thermal Therapy Systems have received EU-wide regulatory approval as medical devices (CE-marked class II) for the treatment of soft tissue lesions. CLS is developing its systems to get CE-mark class III for disposable TRANBERG laser applicators to be used in brain as well as expanding the current CE-mark for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.